FindTrial
Sign In

Precision dosing of intravenous infusion combined with aerosol inhalation of polymyxin B in critically ill patients based on physiological mechanisms and population approach

Precision dosing of intravenous infusion combined with aerosol inhalation of polymyxin B in critically ill patients based on physiological mechanisms and population approach

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062322
Enrollment
Unknown
Registered
2022-08-01
Start date
2022-07-18
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-negative bacteria infection

Interventions

test group:Plasma Concentration Monitoring During Steady State Dosing Intervals
test group:Lavage fluid concentration monitoring in patients requiring fiberoptic bronchoscopy after clinical decision-making

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age >= 18 years old; (2) Critically ill patients diagnosed with Gram-negative bacterial infection; (3) Polymyxin B has been administered continuously for more than 2 days, and the plasma concentration reaches a steady state; (4) Sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients allergic to polymyxin B; (2) Patients who used polymyxin B but did not reach steady state.

Design outcomes

Primary

MeasureTime frame
plasma concentration;ELF concentration;—

Countries

China

Contacts

Public ContactPei Qi
peiqi1028@126.com+86 13170419804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026